{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:38:53Z","timestamp":1793144333632,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.modpat.2023.100125","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T12:43:18Z","timestamp":1675687398000},"page":"100125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-8429","authenticated-orcid":false,"given":"Christopher J.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Bean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Sirohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Hosfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunn-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Krings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2023.100125_bib1","first-page":"532","article-title":"Apocrine carcinoma of the breast. A morphologic and immunocytochemical study","volume":"123","author":"Eusebi","year":"1986","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100125_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2004.06.002","article-title":"Apocrine carcinomas of the breast","volume":"14","author":"Page","year":"2005","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.modpat.2023.100125_bib3","first-page":"1393","article-title":"Apocrine carcinoma of the breast: a comprehensive review","volume":"28","author":"Vranic","year":"2013","journal-title":"Histol Histopathol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100125_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.humpath.2015.05.017","article-title":"Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast","volume":"46","author":"Vranic","year":"2015","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100125_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.2407","article-title":"Refinement of breast cancer classification by molecular characterization of histological special types","volume":"216","author":"Weigelt","year":"2008","journal-title":"J\u00a0Pathol"},{"issue":"11-12","key":"10.1016\/j.modpat.2023.100125_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0344-0338(97)80053-2","article-title":"Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptors accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ","volume":"193","author":"Gatalica","year":"1997","journal-title":"Pathol Res Pract"},{"issue":"8","key":"10.1016\/j.modpat.2023.100125_bib7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PAS.0000000000000671","article-title":"Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100125_bib8","series-title":"World Health Organization Classification of Tumours Editorial Board. Breast Tumours","first-page":"131","article-title":"Carcinoma with apocrine differentiation","author":"Provenzano","year":"2019"},{"issue":"5","key":"10.1016\/j.modpat.2023.100125_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/modpathol.2010.50","article-title":"EGFR and HER-2\/neu expression in invasive apocrine carcinoma of the breast","volume":"23","author":"Vranic","year":"2010","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100125_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/bjc.1990.240","article-title":"Is apocrine differentiation in breast carcinoma of prognostic significance?","volume":"62","author":"Bundred","year":"1990","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2023.100125_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clbc.2012.11.004","article-title":"Immunohistochemically defined subtypes and outcome of apocrine breast cancer","volume":"13","author":"Dellapasqua","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"15","key":"10.1016\/j.modpat.2023.100125_bib12","doi-asserted-by":"crossref","first-page":"24579","DOI":"10.18632\/oncotarget.15597","article-title":"Does invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.modpat.2023.100125_bib13","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41379-020-0589-x","article-title":"Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas","volume":"33","author":"Sun","year":"2020","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100125_bib14","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1016\/j.clbc.2018.02.012","article-title":"Triple negative apocrine carcinomas as a distinct subtype of triple negative breast cancer: a case-control study","volume":"18","author":"Meattini","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"18","key":"10.1016\/j.modpat.2023.100125_bib15","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/cam4.2634","article-title":"Prognosis in triple-negative apocrine carcinomas of the breast: a population-based study","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.modpat.2023.100125_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100125_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (Tils) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.modpat.2023.100125_bib18","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.modpat.2023.100125_bib19","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.modpat.2023.100125_bib20","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2023.100125_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2016.2","article-title":"Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer","volume":"2","author":"Tung","year":"2016","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2023.100125_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/his.13880","article-title":"Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration","volume":"75","author":"Leung","year":"2019","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.modpat.2023.100125_bib23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/modpathol.2017.32","article-title":"Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas","volume":"30","author":"Krings","year":"2017","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100125_bib24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41379-020-00692-8","article-title":"TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer","volume":"34","author":"Ai","year":"2021","journal-title":"Mod Pathol"},{"issue":"7605","key":"10.1016\/j.modpat.2023.100125_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"issue":"269","key":"10.1016\/j.modpat.2023.100125_bib26","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.modpat.2023.100125_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.modpat.2023.100125_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2018.01.021","article-title":"Systematic functional annotation of somatic mutations in cancer","volume":"33","author":"Ng","year":"2018","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.modpat.2023.100125_bib29","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1073\/pnas.0908899107","article-title":"Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase","volume":"107","author":"Chagpar","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.modpat.2023.100125_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccell.2014.09.011","article-title":"The double life of p85","volume":"26","author":"Costa","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib31","doi-asserted-by":"crossref","first-page":"R1028","DOI":"10.1186\/bcr1341","article-title":"Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis","volume":"7","author":"Reis-Filho","year":"2005","journal-title":"Breast Cancer Res"},{"issue":"11","key":"10.1016\/j.modpat.2023.100125_bib32","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41379-018-0081-z","article-title":"Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma","volume":"31","author":"Krings","year":"2018","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100125_bib33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clbc.2020.02.008","article-title":"Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers","volume":"20","author":"Vranic","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.modpat.2023.100125_bib34","series-title":"WHO Classification of Tumours of the Breast","year":"2003"},{"key":"10.1016\/j.modpat.2023.100125_bib35","series-title":"WHO Classification of Tumours of the Breast","year":"2012"},{"issue":"7","key":"10.1016\/j.modpat.2023.100125_bib36","first-page":"8008","article-title":"HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features","volume":"8","author":"Guo","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100125_bib37","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"7418","key":"10.1016\/j.modpat.2023.100125_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib39","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1007\/s13277-016-4924-2","article-title":"Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer","volume":"37","author":"Dirican","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.modpat.2023.100125_bib40","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.modpat.2023.100125_bib41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100125_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.modpat.2023.100125_bib43","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"Tbcrc 032 ib\/ii multicenter study: molecular insights to ar antagonist and pi3k inhibitor efficacy in patients with ar+ metastatic triple-negative breast cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.modpat.2023.100125_bib44","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to cdk4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib45","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-20-0807","article-title":"Activity of combined androgen receptor antagonism and cell cycle inhibition in androgen receptor positive triple negative breast cancer","volume":"20","author":"Christenson","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.modpat.2023.100125_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated her2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.modpat.2023.100125_bib47","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of erbb2 mutation as a biomarker and an actionable target in solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.modpat.2023.100125_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yexmp.2009.09.016","article-title":"PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast","volume":"88","author":"Li","year":"2010","journal-title":"Exp Mol Pathol"},{"issue":"14","key":"10.1016\/j.modpat.2023.100125_bib49","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1158\/0008-5472.CAN-08-2660","article-title":"PIK3CA mutations in in situ and invasive breast carcinomas","volume":"70","author":"Miron","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.modpat.2023.100125_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-009-0406-1","article-title":"Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma","volume":"120","author":"Dunlap","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.modpat.2023.100125_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.humpath.2018.11.005","article-title":"A\u00a0combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer","volume":"85","author":"Tozbikian","year":"2019","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib52","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/his.14118","article-title":"Sry-related high-mobility-group\/HMG box 10 (Sox10) as a sensitive marker for triple-negative breast cancer","volume":"77","author":"Jamidi","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2023.100125_bib53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.humpath.2022.04.006","article-title":"TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma","volume":"125","author":"Yoon","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2023.100125_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.breast.2020.07.003","article-title":"Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy","volume":"53","author":"Montagna","year":"2020","journal-title":"Breast"},{"issue":"15 Pt 1","key":"10.1016\/j.modpat.2023.100125_bib55","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2023.100125_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918790563","article-title":"Survival study of triple-negative and non-triple-negative breast cancer in a Brazilian cohort","volume":"12","author":"Gon\u00e7alves","year":"2018","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100125_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41523-022-00415-z","article-title":"Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (Tnlp) breast cancers","volume":"8","author":"Srivastava","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41571-018-0001-7","article-title":"Triple-negative breast cancers\u2014a panoply of cancer types","volume":"15","author":"Pareja","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.modpat.2023.100125_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2021.01.005","article-title":"Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women","volume":"111","author":"Honma","year":"2021","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100125_bib60","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s12885-020-06998-9","article-title":"Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis","volume":"20","author":"Sanges","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib61","first-page":"1607","article-title":"Triple-negative apocrine breast carcinoma has better prognosis despite poor response to neoadjuvant chemotherapy","volume":"11","author":"Hu","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.modpat.2023.100125_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820943246","article-title":"Avoidance and period-shortening of neoadjuvant chemotherapy against triple-negative breast cancer in stages I and II: importance of ki-67 labeling index and the recognition of apocrine-type lesions","volume":"19","author":"Kubouchi","year":"2020","journal-title":"Technol Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.modpat.2023.100125_bib63","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41416-019-0420-y","article-title":"Molecular apocrine tumours in EORTC 10994\/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes","volume":"120","author":"Bonnefoi","year":"2019","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100125_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"issue":"41","key":"10.1016\/j.modpat.2023.100125_bib65","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25413","article-title":"Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy","volume":"9","author":"Santonja","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.modpat.2023.100125_bib66","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-17-1912","article-title":"Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann\u2019s refined classification","volume":"24","author":"Echavarria","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.modpat.2023.100125_bib67","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr3421","article-title":"Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15","volume":"15","author":"Lehmann-Che","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2023.100125_bib68","doi-asserted-by":"crossref","first-page":"e1123","DOI":"10.1016\/j.clbc.2018.03.012","article-title":"Feasibility of classification of triple negative breast cancer by immunohistochemical surrogate markers","volume":"18","author":"Kim","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2023.100125_bib69","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100125_bib70","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1634\/theoncologist.2015-0312","article-title":"High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer","volume":"21","author":"Alba","year":"2016","journal-title":"Oncologist"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:24:33Z","timestamp":1760232273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0893395223000303"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100125","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100125"}}